Three years after restrictive labeling and labor-intensive postmarketing requirements crushed hopes for a potential blockbuster, GlaxoSmithKline plc handed back the last of its stake in constipation drug Entereg (alvimopan) to Adolor Corp., but analysts see the move as a positive for the Exton, Pa.-based biotech.